After finishing at $10.50 in the prior trading day, C4 Therapeutics Inc (NASDAQ: CCCC) closed at $10.99, up 4.67%. In other words, the price has increased by $+0.49 from its previous closing price. On the day, 3051193 shares were traded.
Ratios:
Our goal is to gain a better understanding of CCCC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.34 and its Current Ratio is at 6.34. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 720.31M and an Enterprise Value of 537.60M. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.32 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 25.90 whereas that against EBITDA is -4.20.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 6.91, while the 200-Day Moving Average is calculated to be 3.74.
Shares Statistics:
The stock has traded on average 16.04M shares per day over the past 3-months and 3.77M shares per day over the last 10 days, according to various share statistics. A total of 60.47M shares are outstanding, with a floating share count of 53.47M. Insiders hold about 22.06% of the company’s shares, while institutions hold 65.90% stake in the company. Shares short for CCCC as of Feb 15, 2024 were 3.18M with a Short Ratio of 0.20, compared to 5.55M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.63% and a Short% of Float of 6.57%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.6, while EPS last year was -$0.71. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.28 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.08 and -$2.52 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$1.92, with 8 analysts recommending between -$0.81 and -$3.01.
